Medivir's TMC435 will be evaluated in a phase II combination study with daclatasvir (BMS 790052) for HCV genotype-1 patients

07-Dec-2011 - Sweden

Medivir AB announced that its development partner, Tibotec Pharmaceuticals, has entered into an agreement with Bristol-Myers Squibb Company.  TMC435, a once daily NS3/4A protease inhibitor (PI) for the treatment of genotype-1 chronic hepatitis C virus (HCV) infection will be investigated in combination with Bristol-Myers Squibb´s investigational NS5A replication complex inhibitor, daclatasvir.

Charlotte Edenius, Executive VP Research & Development, of Medivir commented, "We are very excited to work with Bristol-Myers Squibb to investigate our protease inhibitor, TMC435, in combination with an NS5A replication complex inhibitor to enable the advancement of novel treatment options for people chronically infected with HCV. We believe that an all oral, treatment regimen for HCV would represent a major step towards improved HCV treatments.”

Other news from the department research and development

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?